Scarica l'app Stockscreener
3.89
1.02%
-0.04
Precedente Chiudi:
$3.93
Aprire:
$3.93
Volume 24 ore:
24,409
Relative Volume:
0.35
Capitalizzazione di mercato:
$2.18B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-11.39%
1M Prestazione:
+0.00%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$3.80
$4.1517
Intervallo di 1 settimana:
$3.80
$4.728
Portata 52W:
$3.23
$6.25
Sl Science Holding Ltd Stock (SLBT) Company Profile
Nome
Sl Science Holding Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Compare SLBT vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SLBT
Sl Science Holding Ltd
|
3.89 | 2.20B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
481.27 | 121.95B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
671.52 | 70.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
870.41 | 52.94B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
181.10 | 38.35B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
276.23 | 36.40B | 4.29B | 577.22M | 641.34M | 4.2086 |
Sl Science Holding Ltd Borsa (SLBT) Ultime notizie
Lok Sang Leung Net Worth (2026) - GuruFocus
SL Science presents glioblastoma treatment data at WCP 2026 - Investing.com UK
SL Science presents glioblastoma treatment data at WCP 2026 By Investing.com - Investing.com South Africa
Trevi Therapeutics Shares Surge 13% as Biopharma Investors Cheer Cough Drug Data at London Conference - International Business Times Australia
SL Science Holding Limited Exhibits Breakthrough Gamma Delta T Cell Therapy for Glioblastoma at 2026 World Congress of Basic and Clinical Pharmacology - marketscreener.com
SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology - The Manila Times
SL Science Showcases Preclinical Gamma Delta T Cell Study Demonstrating Glioblastoma Elimination at WCP 2026 - Quiver Quantitative
Preclinical γδ T cells eradicated a brain tumor by day 26 at highest dose - Stock Titan
4DMedical Shares Plunge 15.57% to $3.20 as Volatile ASX Healthcare Stock's Wild Ride Continues This Week - International Business Times Australia
Ericsson, Q32 Bio and other big stocks moving lower in Tuesday’s pre-market session - MSN
Ericsson, Q32 Bio And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Sahm
SL Science seeks US orphan drug designation for γδ T-cell therapy - BioWorld News
Net current asset value per share of SL Science Holding Limited – BOATS:SLBT - TradingView
Number of employees of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Gross margin % of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Price to book ratio of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Net margin % of SL Science Holding Limited – NASDAQ:SLBT - TradingView
SL Science Holding Limited (SLBT-Q) Stock Price and News - The Globe and Mail
Enterprise value to revenue forward of SL Science Holding Limited – BOATS:SLBT - TradingView
Net debt of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Cash flow from investing activities of SL Science Holding Limited – BOATS:SLBT - TradingView
Price to earnings forward of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Enterprise value to EBIT forward of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Enterprise value to EBITDA forward of SL Science Holding Limited – NASDAQ:SLBT - TradingView
EBITDA margin % of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Debt to assets ratio of SL Science Holding Limited – BOATS:SLBT - TradingView
EBITDA per share of SL Science Holding Limited – BOATS:SLBT - TradingView
Debt to equity ratio of SL Science Holding Limited – BOATS:SLBT - TradingView
Enterprise value to EBITDA ratio of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Enterprise value to EBITDA forward of SL Science Holding Limited – BOATS:SLBT - TradingView
EBITDA margin % of SL Science Holding Limited – BOATS:SLBT - TradingView
Enterprise value to EBIT forward of SL Science Holding Limited – BOATS:SLBT - TradingView
Price to earnings forward of SL Science Holding Limited – BOATS:SLBT - TradingView
Price to sales forward of SL Science Holding Limited – BOATS:SLBT - TradingView
Price to book forward of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Enterprise value of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Return on equity % of SL Science Holding Limited – BOATS:SLBT - TradingView
Tangible book value per share of SL Science Holding Limited – BOATS:SLBT - TradingView
EBIT per share of SL Science Holding Limited – NASDAQ:SLBT - TradingView
EBIT per share of SL Science Holding Limited – BOATS:SLBT - TradingView
Cash flow from operating activities of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Cash flow from financing activities of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Asset turnover of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Free cash flow of SL Science Holding Limited – BOATS:SLBT - TradingView
Asset turnover of SL Science Holding Limited – BOATS:SLBT - TradingView
Cash per share of SL Science Holding Limited – BOATS:SLBT - TradingView
Total equity of SL Science Holding Limited – BOATS:SLBT - TradingView
EBITDA of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Total liabilities & shareholders' equities of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Total debt of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Long term debt to total equity ratio of SL Science Holding Limited – BOATS:SLBT - TradingView
Sl Science Holding Ltd Azioni (SLBT) Dati Finanziari
Non sono disponibili dati finanziari per Sl Science Holding Ltd (SLBT). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):